<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00387946</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5514</org_study_id>
    <secondary_id>SSR591813</secondary_id>
    <nct_id>NCT00387946</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)</brief_title>
  <official_title>An International, Seven-week, Double-blind, Placebo-controlled, Two Parallel Group Study to Assess the Efficacy of Dianicline 40 mg Bid as an Aid to Smoking Cessation in Cigarette Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking
      cessation in cigarette smokers. The main secondary objectives are to assess the: craving for
      cigarettes, nicotine withdrawal symptoms, and safety of dianicline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the continuous abstinence from tobacco smoking at every visit during the last 4 weeks of treatment period, i.e. from week 4 to week 7, through direct inquiry of patients, exhaled carbon monoxide (CO) testing, and plasma cotinine measurements</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of Smoking Urges to assess craving for cigarettes; Hughes and Hatsukami Minnesota Withdrawal Scale to measure nicotine withdrawal, number of smoke-free days, and average number of cigarettes smoked from smoking status interview</measure>
  </secondary_outcome>
  <enrollment type="Actual">630</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Tobacco Use Cessation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSR591813L (dianicline)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients, over legal age, smoking at least 10 cigarettes/day as a mean within the 2
             months preceding the screening visit.

        Exclusion Criteria:

          -  Patients who have taken an investigational drug within the past six months prior to
             the screening visit.

          -  Patients who had a previous quit attempt (= or &gt;1 day with the aid of pharmacological
             adjunct) in the previous three months (before screening).

          -  Patients who have smoked or consumed non-tobacco cigarettes or any form of tobacco
             product (other than cigarettes such as cigars, pipes, smokeless tobacco, etc) more
             than 3 times within the 3 months preceding the screening visit.

          -  Patients who currently present with (based on Diagnostic and Statistical Manual of
             Mental Disorders, Fourth Edition [DSM-IV]):

               -  Psychotic disorder

               -  Major depressive episode

          -  Pregnant or breast-feeding women.

          -  Women of childbearing potential not protected by effective contraceptive method of
             birth control and/or who are unwilling or unable to be tested for pregnancy. Medically
             acceptable methods of birth control for this study include approved hormonal
             contraceptive medications or devices, approved intra-uterine contraceptive devices,
             use of two combined barrier methods.

          -  Patients who have suffered from a myocardial infarction, unstable angina or other
             major cardiovascular event within the past week prior to screening.

          -  Patients who have a history of multiple allergic reactions to medications in two drug
             classes.

          -  Patients who have QTcF &gt; 500 ms on the electrocardiogram (ECG).

          -  Patients with mild, moderate or severe renal impairment.

          -  Patients who have an abnormal laboratory test of potential clinical significance at
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative Office</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2006</study_first_submitted>
  <study_first_submitted_qc>October 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2006</study_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>cessation</keyword>
  <keyword>tobacco</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

